Pfizer PFE
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on PFE
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on PFE.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
PFE at a glance
Pfizer (PFE) is trading at $29.39, down 0.20% on the day. Its market value of $167.52B makes it the 116th largest of the 3753 companies we follow.
The stock's 52-week band runs $22.76 to $30.99, and the latest print sits 5.2% under the top end of it. Holders are ahead 26.5% over twelve months, and up 8.7% across the last three months.
On the chart it holds above both the 50-day ($28.73) and 200-day ($26.46) moving averages; RSI is 50, and the last 30 sessions moved at roughly 25% annualized volatility.
For the quarter ended Jun 2026 it reported $15.03B in revenue, up 2.6% from a year earlier, and a net loss of $237.00M.
Buyers are paying 42.0 times trailing earnings. The median for its industry group is 17.8.
17 analysts follow the stock and the average call is "buy". The mean target, $31.29, sits 6.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3740 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
17 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
PFE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.9% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $31.29, 6.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $32.00, so shares trade 8.2% below that estimate. On earnings multiple, it sits in the 95th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Pfizer: the business
Pfizer is a large drugmaker with medicines in cancer, vaccines, heart and inflammation, and it bought Seagen in 2023.
What tends to move it. Falling COVID product sales, patent expiries and its cost cuts against its pipeline are the main points.
Where the case gets weaker. Pfizer's earnings depend on cost cuts and newer pipeline products offsetting both the ongoing decline in COVID-related sales and a wave of patent expiries across its older portfolio. If pipeline products, including those from the Seagen acquisition, underdeliver relative to expectations, the earnings base would keep shrinking with fewer new sources of revenue to replace what is being lost.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.2% | Bearish |
| Price vs 50-day average | +2.3% | Bullish |
| Price vs 200-day average | +11.1% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 49.8 | Bearish |
| MACD (12,26,9) | 0.41 | Bearish |
| Bollinger band position | 37% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 9, 2026 2:30 am ET. Prices can lag the live tape. This is background information, not a recommendation.
How PFE ranks on BeStock
Ranks are among the 3,740 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 42.0x earnings, PFE looks expensive against the market, and trades 136% above the 17.8x median among Drug Manufacturers - General names. The two comparisons do not always agree.
PFE stock: common questions
What is PFE's latest share price?
$29.39 is the latest print for PFE, a move of -0.20% against yesterday's close of $29.45. Today's low and high so far: $28.54 and $29.43.
How large is Pfizer by market value?
Equity value comes to $167.52B at the current price. By that measure it is number 116 of the 3753 names in our coverage.
How is Pfizer valued against its profits?
Buyers pay 42.0 times the last twelve months of profit (EPS $1.36).
Is PFE near its 52-week high or low?
The year's floor is $22.76 and the ceiling $30.99. Shares are 5.2% away from that ceiling.
Does Pfizer pay a dividend?
It does. Payouts over the past twelve months work out to a 5.85% yield; the latest ex-dividend date was November 6, 2026.
Is PFE rated a buy by Wall Street?
Of 17 analysts, 35% say buy, 59% hold and 6% sell. Price targets average $31.29, with the most cautious at $25.00 and the most optimistic at $36.00.
What kind of company is Pfizer?
Pfizer is a large drugmaker with medicines in cancer, vaccines, heart and inflammation, and it bought Seagen in 2023.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on PFE.
Sign in to join the discussion.